Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- gilteritinib
- ripretinib
Interactions between your drugs
gilteritinib ripretinib
Applies to: gilteritinib, ripretinib
Gilteritinib may increase the blood levels of ripretinib in some patients. This may increase the risk and/or severity of side effects such as nausea, vomiting, constipation, diarrhea, hair loss, muscle pain, high blood pressure, heart failure, skin reactions, and skin cancers. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Let your doctor know if you develop redness, pain, blisters, rash, bleeding, or swelling on the palms of your hands or soles of your feet, as these may be signs and symptoms of a potentially severe and painful condition known as Palmar-Plantar Erythrodysesthesia Syndrome (PPES), or hand-foot syndrome. Also seek medical attention if you experience signs and symptoms of heart failure such as fatigue, shortness of breath, protruding neck veins, water retention, and swelling in the abdomen, legs or ankles. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ripretinib food
Applies to: ripretinib
Grapefruit juice may increase the blood levels of certain medications such as ripretinib. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with ripretinib. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Multikinase inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:
- gilteritinib
- ripretinib
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Revuforj
Revuforj is used to treat acute leukemia with a lysine methyltransferase 2A gene translocation ...
Xospata
Xospata (gilteritinib) is used to treat acute myeloid leukemia (AML) with a FLT3 mutation. Xospata ...
Vanflyta
Vanflyta (quizartinib) is an oral targeted treatment called a kinase inhibitor that may be used to ...
Oncovin
Oncovin is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.